Ibnsina PharmaCAI:ISPH -1.23%87 Dividend Yield % is 1.08% as of Jun. 28, 2026, which is 16% below its 10-year median of 1.28. GuruFocus rates CAI:ISPH with a GF Score™ of 87/100 and a GF Value™ of E£10.51 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 69 Medical Distribution companies, Ibnsina Pharma ranks worse than 79.71% on this metric.
As of today (2026-06-28), the Trailing Annual Dividend Yield of Ibnsina Pharma is 1.08%.
Warning Sign:
Ibnsina Pharma stock Dividend Yield % is close to 5-year low.
The historical rank and industry rank for Ibnsina Pharma's Dividend Yield % or its related term are showing as below:
CAI:ISPH'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.57 Med: 1.28 Max: 8.77
Current: 1.08
During the past 10 years, the highest Dividend Yield of Ibnsina Pharma was 8.77%. The lowest was 0.57%. And the median was 1.28%.
CAI:ISPH's Dividend Yield % is ranked worse than 79.71% of 69
companies
in the Medical Distribution industry
Industry Median: 2.94
vs CAI:ISPH: 1.08
During the past 3 years, the average Dividends Per Share Growth Rate was 17.00% per year.
During the past 10 years, the highest 3-Year average Dividends Per Share Growth Rate of Ibnsina Pharma was 30.50% per year. The lowest was 17.00% per year. And the median was 23.75% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Ibnsina Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, COR, CAH: Dividend Yield % Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Dividend Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Ibnsina Pharma Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EGP 0.130000
2026-04-27
2026-04-28
2026-04-29
Cash Dividend
annually
EGP:EGP 1.000000
EGP 0.160000
2025-10-13
2025-10-14
2025-10-15
Cash Dividend
annually
EGP:EGP 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Ibnsina Pharma's Trailing Annual Dividend Yield (%) for Today is calculated as
Ibnsina Pharma's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.13
/
12.05
=
1.08 %
Current Share Price is E£12.05. Ibnsina Pharma's Dividends per Share for the forward twelve months is calculated as E£0.13 * 1 = E£0.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a Dividend Yield % of 1.08% as of Jun. 28, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Ibnsina Pharma and its competitors. This is 16% below median its historical median of 1.28. Over the past decade, Ibnsina Pharma's Dividend Yield % has ranged from 0.57 to 8.77. According to the industry distribution chart, Ibnsina Pharma ranks #55 out of 69 companies in the Medical Distribution industry, placing it in the top 79.7%.
Is Ibnsina Pharma's Dividend Yield % too high?
Ibnsina Pharma's current Dividend Yield % of 1.08% is 16% below median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 8.77. The Medical Distribution industry median Dividend Yield % is 2.94. Ibnsina Pharma's value of 1.08% is 63.3% below this industry median. Based on the distribution chart, Ibnsina Pharma ranks #55 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Dividend Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #55 out of 69 companies for Dividend Yield %. This places Ibnsina Pharma in the lower half of its industry. The industry median Dividend Yield % is 2.94. Ibnsina Pharma's value of 1.08% is 63.3% below this benchmark. Historically, Ibnsina Pharma's own Dividend Yield % has ranged from 0.57 to 8.77 over the past decade. While the company's 10-year median is 1.28 vs. the industry median of 2.94, Ibnsina Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Medical Distribution company?
The median Dividend Yield % among Medical Distribution companies is 2.94, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current Dividend Yield % of 1.08% is 63.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Dividend Yield % is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Dividend Yield % is 1.08%, which is 16% below median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.51, compared to a current price of E£12.05 — trading 14.7% above its estimated fair value. The current Dividend Yield % is 1.08%, which is 16% below median its 10-year median of 1.28 and 63.3% below the Medical Distribution industry median of 2.94. Ibnsina Pharma's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Dividend Yield % is 1.08% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£12.05 is trading 14.7% above its estimated GF Value™ of E£10.51.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Dividend Yield %: 1.08% (16% below median its 10-year median of 1.28)
GF Value™: E£10.51 vs. price of E£12.05 (14.7% above fair value)
Industry Position: 63.3% below the Medical Distribution median (#55 of 69)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
87GF Score
Get the complete analysis for CAI:ISPH
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
